Wuhan Desheng Biochemical Technology Co., Ltd

In the summer of 2026, the global coatings industry will undergo a profound reshaping of its landscape. On July 1st, the former BASF Coatings Business Unit officially began independent operations in M ü nster, Germany under the new brand "Surventis". This independent enterprise with annual sales of approximately 3.9 billion euros, approximately 10700 employees, and a global layout of more than 30 production and research and development bases has become one of the world's leading suppliers of automotive coatings and surface treatment solutions. 1.Giant turns around: BASF Coatings becomes independent, Chinese entities intensively rename This spin off stems from a heavyweight transaction between BASF, Carlyle Fund, and Qatar Investment Authority, with a corporate value of up to 7.7 billion euros. After the transaction is completed, BASF holds 40% of the equity in Svetu, while Carlyle's funds and Qatar Investment Authority jointly hold 60%. At the same time as the equity delivery, several operating entities of Svetu in China are intensively promoting industrial and commercial name changes. Companies such as BASF Coatings Technology (Shanghai), BASF Coatings (Guangdong), BASF Shanghai Coatings (established in 1995 with a registered capital of approximately 609 million yuan), BASF (Shanghai) Coatings Manufacturing, and BASF Coatings (Changchun) have successively completed name changes. Changchun Company mainly serves northern car companies such as FAW Volkswagen and FAW Toyota, while Guangdong Company radiates to the southern Chinese market. A series of changes signify the accelerated formation of the operational framework for Svetu China. 2.Intelligent breakthrough: Svetu collaborates with domestic robots to deeply integrate technology and equipment After leaving the BASF brand endorsement, Svetu is seeking new growth paths, and intelligent cross-border cooperation has become an important lever. On August 13th, Svetu signed a strategic cooperation agreement with Dalian Nasida Automotive Equipment Co., Ltd., a core enterprise in domestic automotive spraying robots. Both parties are jointly promoting the process adaptation and iteration of the new generation of embodied intelligent spraying robots around the theme of "collaboration between materials and robots, integration of processes and equipment". Dalian Nasida has been deeply involved in the field of automotive after-sales equipment for 20 years and is the "hidden champion" in the domestic automotive maintenance equipment industry. According to the cooperation plan, both parties will achieve material process definition, equipment parameters, and intelligent equipment landing process standards. Relying on the AI driven operation system of Dalian Nasida, the robot completes the 3D modeling of the vehicle body through a 3D camera and automatically generates standardized spraying trajectories; Sviatu outputs a parrot (Glasurit) ®) High performance coating systems and precise color matching technology provide material and process standard support for robot operations. Industry data shows that the global market size for complete sets of automatic spraying robot systems will reach 4.6 billion US dollars by 2025, and is expected to grow to 11.15 billion US dollars by 2032. 3.New Desheng's perspective: Upgrading high-end coatings brings new opportunities for upstream raw materials The independent operation and intelligent transformation of Svetu reflect the profound changes that the coating industry is undergoing - from traditional manual spraying to intelligent and automated upgrades, and from solvent based coatings to water-based and environmentally friendly coatings. This trend places higher demands on the performance of coatings themselves, and also means that the value of upstream functional raw materials is being reassessed. Hubei Xindesheng Material Technology Co., Ltd. has been deeply engaged in the fields of fine chemicals and biological raw materials for more than 20 years. In 2026, it was selected as a single champion enterprise in the manufacturing industry of Hubei Province. The company has formed a multidimensional layout in the upstream raw material link of the coating industry: Carbopol series: As an efficient water-soluble rheological modifier, Carbopol has excellent thickening, suspension, and film-forming properties. Carbopol, as a thickener in coating formulations, can effectively regulate the rheological properties of coatings, improve construction performance, and is widely used in water-based coatings, architectural coatings, and other product systems. Tris (tris hydroxymethyl aminomethane): Tris is a weakly basic organic polyol containing trihydroxy and amino groups, which is suitable for water-based coatings, polyurethane coatings, polyester coatings, and functional building coatings. It has multiple functions such as pH buffering adjustment, cross-linking promotion, and dispersion stability in coatings. Its pKa ≈ 8.1, buffer range pH 7.0 – 9.2, accurately adapt to the stability range of water-based acrylic acid, polyurethane, lotion coatings. Tris can also be used as a polyol monomer in the synthesis of polyester and polyurethane resins, endowing coatings with high weather resistance and corrosion resistance. Compared to traditional ammonia and organic amines, Tris has lower volatility, fewer VOCs, and stronger environmental friendliness. CAPS (3- (cyclohexylamine) -1-propanesulfonic acid): CAPS is widely used in the coatings industry and can be used for modifying water-based isocyanate curing agents. CAPS contains sulfonic acid groups, which can adjust the pH value of the coating while increasing its hydrophilicity, helping to prepare more stable and environmentally friendly new water-based coatings. The polyisocyanate modified by CAPS has excellent storage stability and can be used to prepare environmentally friendly high-quality water-based two-component polyurethane coatings. The independent spin off of BASF's coatings business, the official operation of the Svetu brand, the intensive renaming of its entities in China, and the deep cooperation with domestic intelligent equipment enterprises - these series of events mark a new stage of development for the global coatings industry. Intelligence, automation, and environmental friendliness are becoming the core directions for upgrading coating technology. In this process, the requirements for the quality and stability of functional raw materials in coating formulations continue to increase. From the rheological regulation of Carbopol, to the pH buffering and cross-linking promotion of Tris, to the water-based curing agent modification of CAPS - Xindesheng's raw material products are providing key support for the technological upgrade of high-end coatings. We will continue to serve every partner in the paint industry with solid product strength and stable supply capability. Hubei Xindesheng Material Technology Co., Ltd. - Focusing on fine chemical and biological raw materials, assisting in coatings and precise diagnosis

In July 2026, the Jiangxi Provincial Medical Insurance Bureau issued a notice to cancel the eligibility for centralized procurement selection, which caused a stir in the industry. Five companies and over 1400 product specifications voluntarily withdrew from the centralized procurement of liver function, kidney function, myocardial enzymes, and glucose metabolism biochemical reagents, with a maximum of 1170 product specifications cancelled by a single company. Brands such as Siemens and Aiweide are prominently listed. In the view of Hubei Xindesheng Material Technology, the first reaction is not shock, but an expected realization: the mirror of centralized procurement finally reflects the core pain point of the industry's long-term dependence on imported raw materials and lack of cost depth. 1. Why quit? It's not that I don't want to stay, it's that I can't stay According to public information, the reason for the company's exit is summarized in four words - "unprofitable". Behind this is a shocking set of numbers: The average reduction in the collection of liver function biochemical reagents was 68.64%, with the highest being 95.64%; The average reduction rate of renal function myocardial enzyme collection was 77%, with the highest being 92%; The average reduction in sugar metabolism during centralized procurement is 70%, with some products experiencing a reduction of over 98%; Some companies have directly quoted a maximum low price of 0.03 yuan per person. The key conclusion drawn by 21st Century Business Herald in an interview is that once the decline in the field of biochemical IVD exceeds 60%, no matter how much cost is cut, it is difficult to capture profits. When terminal prices are compressed to this extent, a cruel question arises: where does the profit of reagent manufacturers come from? The answer is - it can only come from upstream. The cost of raw materials is the largest variable cost in reagent production. Whoever can reduce the cost of raw materials while ensuring quality has the "ticket" to the era of centralized procurement. On the contrary, those enterprises that have long relied on imported raw materials and lack bargaining power and technological control over upstream are not facing the problem of "making more and earning less", but rather the survival crisis of "selling one box at a loss". 2.An overlooked truth: Domestic raw materials are not "spare tires", they are "trump cards" For a long time, many domestic IVD reagent manufacturers have formed an inertia thinking: imported raw materials have good quality, high stability, and are worth it even if they are a little expensive. Before centralized procurement, this logic holds - there is room for terminal prices, and raw material costs can be passed on. But centralized procurement broke all of this. When terminal prices are locked at extremely low levels, the "premium of imported raw materials" becomes an indigestible cost burden. At the same time, an overlooked truth is emerging: after nearly 20 years of technological accumulation, the top domestic IVD raw material suppliers have the strength to compete with international brands in core categories such as biological buffering agents, enzyme preparations, and color substrates - not only benchmarking international standards in quality, but also forming differentiated advantages in cost-effectiveness, supply stability, and customized services. The essence of centralized procurement is to exchange market capacity for price space. The essence of domestic raw materials is to break through import dependence through technological breakthroughs and free up profit space for downstream enterprises. The combination of the two is the correct path for China's IVD industry to overcome the centralized procurement cycle. 3.Our judgment: The "pit" left by centralized procurement needs to be filled with domestic raw materials From the exit of 5 companies and 1400 product specifications, we can read at least three layers of signals: The first layer signal: Centralized procurement is not a matter of "whether or not to participate", but a matter of "whether or not one is qualified to participate". Qualification does not lie in marketing ability, but in the bottom line of cost. Reagent manufacturers without core raw material support dare not show their trump cards when quoting for centralized procurement, because they do not know where their trump cards are. The second layer signal: the more product specifications are withdrawn, the larger the market space is freed up, and the more urgent the demand for domestically produced raw materials with cost advantages becomes. The products that have withdrawn are not without clinical demand, but rather due to the unsustainable prices offered by the suppliers. Whoever can help reagent manufacturers maintain their price bottom line with lower raw material costs can fill this market vacuum. The third layer signal: the industry is shifting from being "marketing driven" to being "supply chain driven". The core competitiveness of IVD reagent manufacturers is no longer about how wide their channels are or how well-known their brands are, but about how deep their supply chain is, how low their raw material costs are, and how stable their quality is. This is an irreversible trend. 4.Our underlying thinking: Raw material autonomy is not a multiple-choice question, it is a survival question Returning to a fundamental question: why do 5 companies, with 1400 product specifications, choose to give up the market rather than continue supplying? The answer lies upstream in the supply chain. In the past decade, domestic IVD reagent manufacturers have become accustomed to "take it for yourself" - buying imported raw materials, adjusting formulas, packaging and labeling, and making considerable profits. This model ran smoothly before centralized procurement, as the terminal price was sufficient to cover the high premium of imported raw materials. But after the centralized procurement lowers the terminal price, the most fragile link in this chain is exposed: if the raw materials are not in their own hands, they have no initiative in cost, no confidence in quotation, and no guarantee of profit. This is what we often refer to as' getting stuck '- it's not someone else who's holding you back, but your supply chain structure that's holding you back. What Xindesheng is doing is essentially helping reagent manufacturers untangle the "stuck" link. How to solve it? It's not about shouting slogans, it's about focusing on specific things: Replacing imports no longer means compromising quality. Our biological buffer has a stable purity of over 99%, and the enzyme activity and stability are benchmarked against international mainstream brands. The chromogenic substrate has achieved kilogram level mass production - these are not "domestic substitutes", but "domestic competence". Let supply security no longer rely on a single channel. The two production bases in Gedian and Huanggang, with an annual production capacity of 5000 tons for all categories, are not numbers, but the confidence of customers who dare to hand over raw materials to us without worrying about supply interruption. Let cost control no longer rely on squeezing gross profit, but optimize from the source. If a reagent factory uses our enzyme preparation to replace imports, the raw material cost may decrease by an order of magnitude with the same detection performance - this space is the room for maneuver when quoting for centralized procurement. Starting from  2005, to today's selection of Hubei Xindesheng as a single champion enterprise in the manufacturing industry in Hubei Province, we have only done one thing in the past 20 years: to improve the quality of IVD raw materials and connect the chain that relies on imports. This road is not fast, but every step is taken solidly.

On August 14, 2026, the National Healthcare Security Administration officially released the "Guidelines for the Approval of Inspection Medical Service Price Projects (Trial)" (hereinafter referred to as the "Inspection Medical Service Approval Guidelines"), which is the 40th and last batch of medical service price project approval guidelines, marking the basic formation of a unified and standardized medical service price project system nationwide. The guidelines cover major areas such as clinical testing, transfusion and blood type, microbiology and parasites, molecular diagnosis, biochemistry, and immunology, with a total of 662 main items, 114 additional items, and 7 extension items. As a core supplier in the field of in vitro diagnostic (IVD) reagent raw materials, Hubei Xindesheng Material Technology Co., Ltd. believes that this policy adjustment will have a profound impact on the industry, and high-quality and highly stable diagnostic raw materials will play a more critical role under the new price system. 1.  Policy core: Same inspection and same price, pricing not differentiated according to inspection methods The guidelines for inspection projects adhere to a service-oriented approach, with the core change being the principle of no longer setting up separate main projects based on inspection methodology. Taking glucose testing as an example, in the past, most regions established different price items based on different testing methods such as dry chemistry, enzyme method, and enzyme electrode method. However, the new guidelines unify the "glucose testing fee" and no longer distinguish between testing methods, achieving the same testing and price. At the same time, the guidelines clearly stipulate that the consumption of basic material resources required for testing, including reagents, quality control solutions, calibration solutions, etc., shall be included in the pricing cost of testing items, and medical institutions shall not charge patients separately. This means that downstream inspection agencies and IVD reagent production enterprises will face further pressure in cost control, and higher requirements will be put forward for the stability, purity, and cost-effectiveness of raw materials. 2. Industry impact: Raw material quality becomes the key to reducing costs and increasing efficiency Under the new rule of "same test, same price", the fees for inspection items will no longer have price differences due to methodological differences, and the ability to control reagent costs will directly affect the profit margins of medical institutions and reagent manufacturers. This has prompted the entire IVD industry chain to pay more attention to the quality and cost efficiency of upstream raw materials - high-purity and highly stable diagnostic raw materials can help reduce batch differences, lower duplicate detection rates, improve the accuracy and consistency of test results, and thus achieve better economic benefits within the established fee framework. As pointed out in the guidelines, the in vitro diagnostic reagent market in China has continued to grow in recent years, with a market size of approximately 130 billion yuan by 2025. The standardization and unification of national inspection price items will effectively lead the high-quality development of inspection disciplines and promote mutual recognition of inspection results. In this process, the technical strength and product quality of upstream raw material suppliers will become an important foundation to support the high-quality development of the industry. 3. New Desheng: Using high-quality raw materials to assist the industry in responding to new regulations Hubei Xindesheng Material Technology Co., Ltd. has long focused on the field of IVD reagent raw materials, deeply cultivating the research and development, production, and sales of core products such as blood vessel additives, biological buffering agents, chemiluminescence reagents, color reagents, enzyme preparations, etc. The company was formerly known as Wuhan Desheng Biochemical, established in 2005. After years of technological accumulation and continuous innovation, it has grown into a core enterprise in the field of IVD reagent raw materials in China. In response to the industry changes brought about by this policy adjustment, New Desheng's core product system can provide strong support for downstream customers: Biological buffer series: The company relies on the advantages of chemical synthesis technology to form a matrix of more than 50 products such as Tris, HEPES, MOPS, etc., with a stable purity of over 99%, and can customize indicators according to customer application scenarios. High purity buffering agents provide a stable reaction environment for diagnostic reagents, helping to ensure the accuracy and inter batch consistency of test results. Enzyme Preparation Series: The company has developed a new generation of high-purity and highly stable enzyme preparations, including key indicator detection materials such as lactate dehydrogenase (LDH), uricase (UO), creatine kinase isoenzyme (CKMB), etc. Enzyme preparations with high activity and stability can effectively enhance the detection sensitivity and specificity of the reagent kit, helping downstream reagent manufacturers achieve better product performance within the established fee framework. Color developing substrate series: TOOS, MAOS and other products are benchmarked against international standards, with some indicators surpassing them, helping reagents improve detection indicators and reduce background interference. Blood collection tube additives: Heparin lithium, Heparin sodium, EDTA dipotassium, tripotassium, serum separation gel and other blood sample pretreatment product systems, widely used in clinical laboratory and other fields. The company has two R&D and production bases in Gedian and Huanggang (70 acres), with an annual production capacity of 5000 tons for all categories. With solid technical strength and a sound quality control system, Hubei Xindesheng was successfully selected as a single champion enterprise in the manufacturing industry of Hubei Province in 2026, marking that the company has reached the forefront of the IVD reagent raw material subdivision track in China. The release of the inspection project approval guidelines marks a new stage of unified and standardized management of medical service pricing projects nationwide. For the IVD reagent raw material industry, the importance of quality, stability, and cost-effectiveness will be further highlighted. Hubei Xindesheng Material Technology Co., Ltd. will adhere to craftsmanship and quality, continuously increase research and development investment, empower the development of IVD in vitro diagnostics industry with more stable products and more professional technical support, and help the industry achieve high-quality development in the new policy environment.

1. Why is CK-MB higher in children than in adults? In clinical biochemical testing, creatine kinase isoenzyme (CK-MB) is an important indicator for evaluating myocardial injury. Many inspectors have found that when using heparin lithium anticoagulant blood collection tubes to collect blood samples from children, the phenomenon of CK-MB detection values being significantly higher than that of adults. This phenomenon is not due to the higher incidence rate of myocardial injury in children, but is closely related to multiple factors in the use of blood collection vessels. 2. Core cause analysis (1) The intrinsic effect of heparin lithium anticoagulant on CK-MB detection Research has shown that there is a significant difference in CK-MB detection results between heparin lithium anticoagulant plasma and serum. The correlation between CK-MB values measured by heparin lithium anticoagulant plasma and serum test results is poor. The literature clearly states that items such as CK-MB should not be measured using heparin lithium anticoagulant plasma samples. This means that the heparin lithium blood collection tube itself will cause certain interference with CK-MB detection, which exists in different populations, but is more prominent in children. (2) Insufficient filling of blood collection tubes - the primary factor for elevated CK-MB in children There is a significant difference in blood collection between children and adults. Adult blood collection tubes are usually designed with a blood collection volume of 4ml, while pediatric blood collection volumes are generally 3ml. When the heparin lithium blood collection tube fails to reach the recommended filling volume, the vacuum pressure inside the tube becomes too high and the relative concentration of heparin increases, which can exacerbate red blood cell rupture (hemolysis) and release high concentrations of intracellular contents. Research has confirmed that insufficient filling of blood collection tubes can lead to significant changes in enzymatic indicators such as CK and GGT. Another study suggests that short drawn heparin lithium tubes may not be suitable for testing projects such as CK. Children have small blood volume and thin blood vessels, making blood collection difficult and more prone to insufficient blood collection. Insufficient filling leads to high heparin concentration, while indicators such as CK-MB in plasma increase with increasing heparin concentration. This is precisely the pathophysiological mechanism by which elevated CK-MB levels in heparin lithium blood collection tubes are more common in children than in adults. (3) Hemolysis is the direct driving force behind the pseudo elevation of CK-MB Hemolysis is the direct cause of false elevation of CK-MB. Red blood cells contain high concentrations of enzymes such as creatine kinase (CK), which are released into the plasma after hemolysis, leading to artificially elevated detection values. Due to crying, lack of cooperation, and thin blood vessels during blood collection in children, the difficulty and operation time of puncture are high, and the high vacuum pressure caused by insufficient filling of blood collection vessels makes the risk of hemolysis in children's specimens much higher than that in adults. Research has shown that blood samples in heparin lithium tubes are more sensitive to hemolysis, and a hemolysis index exceeding 20 can interfere with CK-MB detection. 3. Response suggestions (1) Select specialized blood collection tubes suitable for children's blood collection It is recommended to use micro blood collection tubes specifically designed for children in clinical practice. These products have a reasonable blood collection volume design, accurate matching of anticoagulant content and blood collection volume, which can effectively avoid the problem of high heparin concentration caused by insufficient filling. (2) Standardize blood collection procedures Ensure that the blood collection tube is filled to the recommended blood volume; After blood collection, gently invert and mix 6-8 times to avoid severe shaking; Soothe the patient's emotions before blood collection, choose a suitable blood collection site, and try to be as precise as possible. (3) Establish a reference system for children's plasma testing Given the differences in CK-MB and other parameters between heparin lithium anticoagulant plasma and serum, it is recommended that clinical laboratories gradually establish a reference range for biochemical testing of pediatric plasma to avoid misjudging plasma test results based on serum standards. Hubei Xindesheng Material Technology Co., Ltd. is a high-tech enterprise specializing in the field of IVD reagent raw materials. It was selected as a single champion enterprise in the manufacturing industry of Hubei Province in 2025. The company was founded in 2005 and specializes in the research, development, production, and sales of core products such as blood vessel additives, biological buffering agents, and chemiluminescence reagents. In terms of heparin lithium products, the potency of Desheng heparin lithium is ≥ 150IU/mg. The company adheres to the product concept of "precision, stability, and innovation", and continues to provide high-quality anticoagulant raw materials such as heparin lithium for blood collection tube production enterprises. We are well aware that high-quality raw materials are the foundation of precise testing. Desheng will continue to use a rigorous scientific research attitude and strict quality control to help clinical testing become more accurate and reliable.